2nd Edition of Cell & Gene Therapy World Conference(CGTWC) 2026

Scientific Sessions

Global Access and Equity: Bridging the CGT Innovation Gap

Ensuring global access and equity in CGTs is critical to realise the promise of life-changing therapies. Achieving this aim will be utterly dependent on the coordinated efforts across research, regulation, manufacturing, and health systems to ensure CGT therapies are both accessible and affordable around the world. In our Cell & Gene Therapy World Congress, international leaders in policy, healthcare, and biotechnology will discuss strategies to improve access and strengthen collaboration across borders. This discussion will involve deliberations related to technology transfer, workforce development, regulatory harmonisation, and creating sustainable funding mechanisms that ensure inclusive participation in CGT innovation.

Related Sessions

CRISPR Cas9 and Beyond: Emerging Genome Editing Platforms
Precision Genome Editing: From Target Discovery to Clinical Application
Engineering the Immune System: Gene and Cell Based Modulation
Non Viral Gene Delivery Strategies: Safety, Scalability, and Translation
Stem Cell Derived Therapeutics: iPSCs, Organoids and Tissue Engineering
Allogeneic vs Autologous Cell Therapies: Manufacturing, Efficacy, and Access
Manufacturing for Personalized Medicine: Customised Cell Products at Scale
Analytics, Potency Assays, and Rapid Release Strategies
CGTs for Monogenic Disorders: Delivering the Cure
Gene and Cell Therapies in Oncology: CAR T, NK, TCR, Oncolytic Approaches
Neurological and Neurodegenerative Disease Applications of CGTs
Market Access, Health Economics, and Reimbursement in CGT
Global Access and Equity: Bridging the CGT Innovation Gap
The Future Landscape of Cell and Gene Therapies: 2030 and Beyond
Cell and Gene Therapy Clinical Development
Cell and Gene Therapy Pipeline Analysis